PremiumThe FlyPalisade Bio to present preclinical results for PALI-2108 Palisade Bio initiated with a Buy at Brookline Palisade Bio price target lowered to $8 from $22.50 at Maxim PremiumThe FlyPalisade Bio files to sell common stock, warrants, no amount given Palisade Bio received No Objection Letter from Health Canada for Phase 1 study Palisade Bio CEO Finley’s Revised Employment and Compensation Deal PremiumThe FlyStarbucks picks new CEO, Google unveils Pixel 9: Tuesday Buzz Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz Palisade Bio reports Q2 EPS ($3.32) vs ($7.93) last year 
